| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 78 | 2023 | 153 | 11.060 |
Why?
|
| Carcinoma, Squamous Cell | 76 | 2023 | 239 | 9.150 |
Why?
|
| Laryngeal Neoplasms | 35 | 2024 | 53 | 4.680 |
Why?
|
| Oropharyngeal Neoplasms | 27 | 2024 | 34 | 3.210 |
Why?
|
| Mouth Neoplasms | 13 | 2023 | 32 | 2.660 |
Why?
|
| Neoplasm Recurrence, Local | 24 | 2021 | 302 | 2.350 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 8 | 2022 | 35 | 1.960 |
Why?
|
| Papillomavirus Infections | 14 | 2024 | 127 | 1.800 |
Why?
|
| Laryngectomy | 19 | 2020 | 23 | 1.750 |
Why?
|
| Neoplasm Staging | 36 | 2024 | 460 | 1.610 |
Why?
|
| Papillomaviridae | 17 | 2024 | 60 | 1.480 |
Why?
|
| Neoadjuvant Therapy | 9 | 2024 | 72 | 1.420 |
Why?
|
| Biomarkers, Tumor | 13 | 2022 | 465 | 1.410 |
Why?
|
| Prognosis | 40 | 2022 | 1591 | 1.300 |
Why?
|
| Middle Aged | 99 | 2024 | 16535 | 1.170 |
Why?
|
| Neck Dissection | 12 | 2024 | 19 | 1.160 |
Why?
|
| Disease-Free Survival | 23 | 2021 | 233 | 1.130 |
Why?
|
| Cytokines | 6 | 2022 | 911 | 1.050 |
Why?
|
| Male | 108 | 2024 | 27971 | 1.000 |
Why?
|
| Neoplasm Invasiveness | 15 | 2023 | 248 | 0.990 |
Why?
|
| DNA Methylation | 6 | 2020 | 273 | 0.990 |
Why?
|
| Immunotherapy | 4 | 2021 | 237 | 0.960 |
Why?
|
| Female | 106 | 2024 | 31250 | 0.940 |
Why?
|
| Salvage Therapy | 11 | 2020 | 74 | 0.920 |
Why?
|
| Humans | 151 | 2024 | 60132 | 0.910 |
Why?
|
| Survival Rate | 25 | 2020 | 793 | 0.880 |
Why?
|
| Aged | 68 | 2024 | 13581 | 0.830 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2022 | 405 | 0.820 |
Why?
|
| Survival Analysis | 21 | 2019 | 558 | 0.810 |
Why?
|
| Chemoradiotherapy | 13 | 2024 | 50 | 0.790 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2018 | 20 | 0.770 |
Why?
|
| Surgical Flaps | 5 | 2009 | 112 | 0.760 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2021 | 651 | 0.700 |
Why?
|
| Antineoplastic Agents | 11 | 2022 | 647 | 0.670 |
Why?
|
| Treatment Outcome | 38 | 2024 | 5262 | 0.640 |
Why?
|
| Retrospective Studies | 35 | 2024 | 6139 | 0.640 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2019 | 17 | 0.640 |
Why?
|
| Isoflavones | 1 | 2019 | 17 | 0.640 |
Why?
|
| Follow-Up Studies | 21 | 2019 | 2362 | 0.630 |
Why?
|
| Lymph Nodes | 7 | 2019 | 215 | 0.630 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2013 | 61 | 0.610 |
Why?
|
| Adult | 53 | 2024 | 15985 | 0.600 |
Why?
|
| Otorhinolaryngologic Neoplasms | 4 | 2010 | 5 | 0.580 |
Why?
|
| Prospective Studies | 28 | 2017 | 3131 | 0.560 |
Why?
|
| Risk Assessment | 19 | 2017 | 1937 | 0.550 |
Why?
|
| Cisplatin | 12 | 2022 | 119 | 0.540 |
Why?
|
| Dietary Supplements | 1 | 2019 | 249 | 0.530 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2018 | 391 | 0.530 |
Why?
|
| Larynx | 5 | 2021 | 15 | 0.520 |
Why?
|
| Human papillomavirus 16 | 5 | 2020 | 17 | 0.520 |
Why?
|
| Genes, p53 | 3 | 2016 | 53 | 0.510 |
Why?
|
| Radiotherapy, Conformal | 3 | 2005 | 20 | 0.500 |
Why?
|
| Quality of Life | 14 | 2024 | 1140 | 0.490 |
Why?
|
| Combined Modality Therapy | 17 | 2017 | 361 | 0.490 |
Why?
|
| Interleukin-6 | 7 | 2015 | 309 | 0.480 |
Why?
|
| Histamine H2 Antagonists | 1 | 2014 | 12 | 0.480 |
Why?
|
| Cohort Studies | 21 | 2018 | 2479 | 0.470 |
Why?
|
| Tissue Array Analysis | 6 | 2020 | 31 | 0.470 |
Why?
|
| Proportional Hazards Models | 13 | 2023 | 679 | 0.470 |
Why?
|
| Proton Pump Inhibitors | 1 | 2014 | 38 | 0.470 |
Why?
|
| Gastroesophageal Reflux | 1 | 2014 | 78 | 0.460 |
Why?
|
| Induction Chemotherapy | 6 | 2022 | 33 | 0.430 |
Why?
|
| Mouth | 3 | 2021 | 32 | 0.430 |
Why?
|
| Deglutition Disorders | 5 | 2013 | 44 | 0.420 |
Why?
|
| Aged, 80 and over | 24 | 2019 | 5197 | 0.420 |
Why?
|
| Parotid Gland | 2 | 2019 | 11 | 0.400 |
Why?
|
| Cell Line, Tumor | 11 | 2021 | 1384 | 0.400 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2020 | 53 | 0.390 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2011 | 7 | 0.380 |
Why?
|
| Deglutition | 5 | 2020 | 19 | 0.360 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2019 | 77 | 0.350 |
Why?
|
| ErbB Receptors | 4 | 2012 | 113 | 0.350 |
Why?
|
| Ethics, Medical | 1 | 2010 | 38 | 0.350 |
Why?
|
| Truth Disclosure | 1 | 2010 | 54 | 0.340 |
Why?
|
| Shoulder | 4 | 2021 | 23 | 0.330 |
Why?
|
| Lymphatic Metastasis | 6 | 2016 | 70 | 0.330 |
Why?
|
| Neoplastic Stem Cells | 3 | 2021 | 203 | 0.320 |
Why?
|
| Viral Vaccines | 1 | 2009 | 49 | 0.320 |
Why?
|
| Adenoviridae | 1 | 2009 | 120 | 0.320 |
Why?
|
| Tongue Neoplasms | 1 | 2008 | 2 | 0.310 |
Why?
|
| Tracheostomy | 2 | 2020 | 35 | 0.310 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2020 | 8 | 0.310 |
Why?
|
| Deoxycytidine | 2 | 2014 | 39 | 0.310 |
Why?
|
| Orthognathic Surgical Procedures | 1 | 2008 | 3 | 0.310 |
Why?
|
| Paclitaxel | 5 | 2015 | 91 | 0.300 |
Why?
|
| Bone Plates | 1 | 2008 | 30 | 0.300 |
Why?
|
| Antigens, CD | 2 | 2018 | 344 | 0.280 |
Why?
|
| Mutation | 4 | 2018 | 2471 | 0.280 |
Why?
|
| Smoking | 8 | 2016 | 835 | 0.270 |
Why?
|
| Lymph Node Excision | 3 | 2019 | 37 | 0.270 |
Why?
|
| Patient Selection | 4 | 2017 | 453 | 0.270 |
Why?
|
| Fluorouracil | 9 | 2022 | 55 | 0.270 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2016 | 34 | 0.270 |
Why?
|
| Indomethacin | 2 | 2020 | 20 | 0.270 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 71 | 0.260 |
Why?
|
| Genomics | 1 | 2009 | 314 | 0.260 |
Why?
|
| Probability | 4 | 2010 | 173 | 0.260 |
Why?
|
| B7-H1 Antigen | 3 | 2022 | 53 | 0.260 |
Why?
|
| Longitudinal Studies | 8 | 2023 | 1237 | 0.250 |
Why?
|
| Postoperative Complications | 8 | 2017 | 1172 | 0.250 |
Why?
|
| Organ Preservation | 5 | 2024 | 18 | 0.250 |
Why?
|
| Nasopharyngeal Neoplasms | 3 | 2014 | 8 | 0.240 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2020 | 621 | 0.240 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2015 | 6 | 0.240 |
Why?
|
| Xerostomia | 2 | 2007 | 10 | 0.240 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2013 | 56 | 0.230 |
Why?
|
| Michigan | 8 | 2018 | 39 | 0.230 |
Why?
|
| Statistics, Nonparametric | 5 | 2013 | 209 | 0.230 |
Why?
|
| Parotid Neoplasms | 2 | 2019 | 4 | 0.230 |
Why?
|
| Papillomavirus E7 Proteins | 3 | 2020 | 6 | 0.220 |
Why?
|
| Radiation Injuries | 1 | 2004 | 62 | 0.220 |
Why?
|
| Tocopherols | 2 | 2020 | 11 | 0.210 |
Why?
|
| Membrane Proteins | 2 | 2020 | 847 | 0.210 |
Why?
|
| Salivary Glands | 1 | 2003 | 46 | 0.210 |
Why?
|
| Biopsy | 3 | 2018 | 376 | 0.210 |
Why?
|
| Health Behavior | 4 | 2013 | 472 | 0.210 |
Why?
|
| Otolaryngology | 1 | 2002 | 24 | 0.200 |
Why?
|
| Genetic Therapy | 1 | 2009 | 744 | 0.200 |
Why?
|
| Aspirin | 1 | 2023 | 171 | 0.200 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2002 | 14 | 0.200 |
Why?
|
| Microbiota | 1 | 2023 | 104 | 0.200 |
Why?
|
| Tristetraprolin | 2 | 2013 | 7 | 0.200 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 15 | 0.190 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2021 | 31 | 0.190 |
Why?
|
| Organ Sparing Treatments | 2 | 2024 | 15 | 0.190 |
Why?
|
| Neoplasm Metastasis | 4 | 2015 | 196 | 0.190 |
Why?
|
| Cause of Death | 3 | 2017 | 205 | 0.190 |
Why?
|
| Neoplasm Proteins | 4 | 2014 | 277 | 0.190 |
Why?
|
| Cutaneous Fistula | 3 | 2017 | 7 | 0.190 |
Why?
|
| Pharyngeal Diseases | 3 | 2017 | 10 | 0.190 |
Why?
|
| Epithelium | 1 | 2021 | 97 | 0.180 |
Why?
|
| Carcinoma | 4 | 2014 | 117 | 0.180 |
Why?
|
| Research | 1 | 2002 | 190 | 0.180 |
Why?
|
| Intercellular Junctions | 1 | 2020 | 8 | 0.180 |
Why?
|
| Saliva | 2 | 2023 | 96 | 0.180 |
Why?
|
| 5-Methylcytosine | 1 | 2020 | 20 | 0.180 |
Why?
|
| Omeprazole | 1 | 2020 | 4 | 0.180 |
Why?
|
| Anti-Ulcer Agents | 1 | 2020 | 8 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2021 | 316 | 0.180 |
Why?
|
| Multivariate Analysis | 8 | 2018 | 928 | 0.180 |
Why?
|
| Virus Integration | 2 | 2017 | 32 | 0.180 |
Why?
|
| Keratinocytes | 1 | 2020 | 63 | 0.180 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 71 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 31 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2020 | 17 | 0.170 |
Why?
|
| Tumor Escape | 1 | 2020 | 16 | 0.170 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 213 | 0.170 |
Why?
|
| Facial Nerve Injuries | 1 | 2019 | 4 | 0.170 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2017 | 53 | 0.170 |
Why?
|
| Employment | 2 | 2015 | 136 | 0.170 |
Why?
|
| Education, Medical, Graduate | 1 | 2002 | 319 | 0.170 |
Why?
|
| Zinc | 1 | 2020 | 91 | 0.170 |
Why?
|
| Monitoring, Intraoperative | 1 | 2019 | 46 | 0.170 |
Why?
|
| Electromyography | 1 | 2019 | 87 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 483 | 0.160 |
Why?
|
| Predictive Value of Tests | 8 | 2017 | 1035 | 0.160 |
Why?
|
| Remission Induction | 3 | 2009 | 139 | 0.160 |
Why?
|
| Diet | 3 | 2012 | 637 | 0.160 |
Why?
|
| Tracheal Neoplasms | 1 | 2019 | 3 | 0.160 |
Why?
|
| Mitochondrial Proteins | 1 | 2020 | 99 | 0.160 |
Why?
|
| Peripheral Nerves | 2 | 2022 | 30 | 0.160 |
Why?
|
| Carboplatin | 4 | 2015 | 40 | 0.160 |
Why?
|
| Proteolysis | 1 | 2020 | 137 | 0.160 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 94 | 0.160 |
Why?
|
| Antigens, CD1 | 2 | 2015 | 42 | 0.160 |
Why?
|
| Pneumonia, Aspiration | 2 | 2013 | 17 | 0.160 |
Why?
|
| Vimentin | 1 | 2018 | 18 | 0.160 |
Why?
|
| Integrin alpha Chains | 1 | 2018 | 10 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 201 | 0.150 |
Why?
|
| Neoplasms, Nerve Tissue | 1 | 2018 | 1 | 0.150 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 304 | 0.150 |
Why?
|
| Cadherins | 1 | 2018 | 69 | 0.150 |
Why?
|
| Elective Surgical Procedures | 1 | 2019 | 108 | 0.150 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 60 | 0.150 |
Why?
|
| Repressor Proteins | 2 | 2020 | 336 | 0.150 |
Why?
|
| Respiratory Tract Fistula | 1 | 2017 | 3 | 0.150 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 48 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 3 | 2023 | 86 | 0.150 |
Why?
|
| Biomarkers | 6 | 2016 | 1213 | 0.150 |
Why?
|
| Mice | 10 | 2023 | 10343 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 184 | 0.150 |
Why?
|
| bcl-X Protein | 2 | 2008 | 19 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2008 | 299 | 0.140 |
Why?
|
| Capecitabine | 1 | 2017 | 10 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2017 | 39 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 712 | 0.140 |
Why?
|
| Paraffin Embedding | 3 | 2019 | 16 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 685 | 0.140 |
Why?
|
| HIV Seropositivity | 1 | 2017 | 82 | 0.140 |
Why?
|
| Risk Factors | 11 | 2017 | 5082 | 0.140 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 281 | 0.140 |
Why?
|
| DNA, Neoplasm | 2 | 2007 | 51 | 0.140 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 42 | 0.130 |
Why?
|
| Positron-Emission Tomography | 2 | 2016 | 174 | 0.130 |
Why?
|
| Immunologic Memory | 1 | 2018 | 284 | 0.130 |
Why?
|
| Speech | 3 | 2020 | 61 | 0.130 |
Why?
|
| Microcirculation | 2 | 2009 | 51 | 0.130 |
Why?
|
| Endoscopy | 1 | 2017 | 104 | 0.130 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 144 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2015 | 639 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 1481 | 0.130 |
Why?
|
| Xanthophylls | 1 | 2015 | 24 | 0.130 |
Why?
|
| Cigarette Smoking | 1 | 2016 | 52 | 0.130 |
Why?
|
| Leisure Activities | 1 | 2015 | 28 | 0.130 |
Why?
|
| Cell Movement | 4 | 2020 | 425 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 197 | 0.120 |
Why?
|
| Health Status Indicators | 4 | 2004 | 97 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2023 | 194 | 0.120 |
Why?
|
| Radiography | 2 | 2009 | 514 | 0.120 |
Why?
|
| RNA Stability | 2 | 2013 | 94 | 0.120 |
Why?
|
| Animals | 12 | 2023 | 19768 | 0.120 |
Why?
|
| Oral Surgical Procedures | 1 | 2014 | 1 | 0.110 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2013 | 2 | 0.110 |
Why?
|
| Enteral Nutrition | 4 | 2008 | 57 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2013 | 9 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 1565 | 0.110 |
Why?
|
| Tumor Virus Infections | 1 | 2013 | 37 | 0.110 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2013 | 9 | 0.110 |
Why?
|
| Human papillomavirus 6 | 1 | 2013 | 4 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 80 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 225 | 0.110 |
Why?
|
| Spasm | 1 | 2013 | 9 | 0.110 |
Why?
|
| Neck Muscles | 1 | 2013 | 9 | 0.110 |
Why?
|
| Young Adult | 7 | 2019 | 4396 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 172 | 0.100 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 28 | 0.100 |
Why?
|
| Mandibular Diseases | 1 | 2012 | 2 | 0.100 |
Why?
|
| Free Tissue Flaps | 1 | 2012 | 2 | 0.100 |
Why?
|
| Osteoradionecrosis | 1 | 2012 | 3 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 417 | 0.100 |
Why?
|
| Mandible | 1 | 2012 | 11 | 0.100 |
Why?
|
| Smoking Cessation | 2 | 2016 | 538 | 0.100 |
Why?
|
| Risk | 2 | 2010 | 377 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 59 | 0.100 |
Why?
|
| Quinazolines | 1 | 2012 | 22 | 0.100 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2009 | 13 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 1 | 2014 | 183 | 0.100 |
Why?
|
| Wound Healing | 3 | 2017 | 177 | 0.100 |
Why?
|
| Facial Nerve | 2 | 2019 | 16 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 73 | 0.100 |
Why?
|
| Algorithms | 2 | 2016 | 1002 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2012 | 34 | 0.100 |
Why?
|
| Neoplasm Grading | 3 | 2018 | 75 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2022 | 98 | 0.100 |
Why?
|
| Micronutrients | 1 | 2011 | 29 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 171 | 0.090 |
Why?
|
| Gluconates | 1 | 2011 | 4 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2010 | 54 | 0.090 |
Why?
|
| Comorbidity | 5 | 2016 | 1098 | 0.090 |
Why?
|
| Injections, Subcutaneous | 1 | 2011 | 71 | 0.090 |
Why?
|
| Cell Division | 2 | 2010 | 443 | 0.090 |
Why?
|
| Incidence | 3 | 2017 | 1265 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 760 | 0.090 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2010 | 13 | 0.090 |
Why?
|
| Side-Population Cells | 1 | 2010 | 4 | 0.090 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2010 | 16 | 0.090 |
Why?
|
| Overweight | 1 | 2012 | 249 | 0.090 |
Why?
|
| Interleukin-2 | 1 | 2011 | 164 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 1100 | 0.090 |
Why?
|
| Immunity | 2 | 2021 | 97 | 0.090 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 2505 | 0.090 |
Why?
|
| Hypopharynx | 1 | 2009 | 4 | 0.080 |
Why?
|
| Injections, Intralesional | 1 | 2009 | 13 | 0.080 |
Why?
|
| Oropharynx | 1 | 2009 | 12 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 23 | 0.080 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2010 | 94 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2009 | 62 | 0.080 |
Why?
|
| Cartilage | 1 | 2009 | 36 | 0.080 |
Why?
|
| Sex Factors | 2 | 2016 | 969 | 0.080 |
Why?
|
| Larynx, Artificial | 1 | 2009 | 4 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2011 | 262 | 0.080 |
Why?
|
| Papillomavirus Vaccines | 1 | 2010 | 72 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2009 | 257 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2010 | 146 | 0.080 |
Why?
|
| Glossectomy | 1 | 2008 | 3 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2009 | 79 | 0.080 |
Why?
|
| Interferon-gamma | 1 | 2011 | 551 | 0.080 |
Why?
|
| Graft Survival | 1 | 2009 | 279 | 0.080 |
Why?
|
| Logistic Models | 4 | 2017 | 1259 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 183 | 0.080 |
Why?
|
| Transcriptome | 2 | 2022 | 337 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 584 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2009 | 264 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 525 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2013 | 854 | 0.070 |
Why?
|
| Carotenoids | 2 | 2020 | 72 | 0.070 |
Why?
|
| Biopsy, Needle | 3 | 2013 | 129 | 0.070 |
Why?
|
| Vaccination | 1 | 2010 | 344 | 0.070 |
Why?
|
| Cell Separation | 3 | 2015 | 147 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 457 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2017 | 849 | 0.070 |
Why?
|
| Thyroglossal Cyst | 1 | 2007 | 3 | 0.070 |
Why?
|
| Coccidioidomycosis | 1 | 2007 | 11 | 0.070 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2008 | 119 | 0.070 |
Why?
|
| Prevalence | 3 | 2016 | 1300 | 0.070 |
Why?
|
| Body Mass Index | 4 | 2013 | 892 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 1136 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2009 | 334 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2021 | 860 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 498 | 0.060 |
Why?
|
| Blood Urea Nitrogen | 1 | 2005 | 9 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2021 | 1999 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 2013 | 454 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2017 | 1066 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 712 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 351 | 0.060 |
Why?
|
| Ethanol | 1 | 2008 | 307 | 0.060 |
Why?
|
| Creatinine | 1 | 2005 | 123 | 0.060 |
Why?
|
| Alcoholism | 1 | 2008 | 308 | 0.060 |
Why?
|
| Adolescent | 3 | 2014 | 5958 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2007 | 462 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2021 | 2891 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2019 | 125 | 0.060 |
Why?
|
| Obesity | 1 | 2012 | 1192 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2013 | 200 | 0.060 |
Why?
|
| Skull Base Neoplasms | 1 | 2004 | 5 | 0.060 |
Why?
|
| Sick Role | 1 | 2004 | 15 | 0.060 |
Why?
|
| Pectoralis Muscles | 1 | 2004 | 5 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2017 | 38 | 0.060 |
Why?
|
| Chondrosarcoma | 1 | 2003 | 6 | 0.060 |
Why?
|
| Gastrostomy | 3 | 2012 | 33 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 2 | 2015 | 68 | 0.050 |
Why?
|
| In Situ Hybridization | 2 | 2014 | 215 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 77 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 449 | 0.050 |
Why?
|
| Swine, Miniature | 1 | 2003 | 8 | 0.050 |
Why?
|
| RNA, Neoplasm | 2 | 2018 | 34 | 0.050 |
Why?
|
| Age Factors | 3 | 2016 | 1525 | 0.050 |
Why?
|
| Weight Loss | 1 | 2005 | 264 | 0.050 |
Why?
|
| Cell Transplantation | 1 | 2003 | 39 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2004 | 217 | 0.050 |
Why?
|
| Muscles | 1 | 2004 | 171 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 21 | 0.050 |
Why?
|
| Cell Culture Techniques | 2 | 2015 | 179 | 0.050 |
Why?
|
| Dura Mater | 1 | 2003 | 35 | 0.050 |
Why?
|
| Keratins | 1 | 2022 | 31 | 0.050 |
Why?
|
| Hospitals, University | 2 | 2013 | 51 | 0.050 |
Why?
|
| Spinal Nerves | 1 | 2002 | 5 | 0.050 |
Why?
|
| Factor VIII | 1 | 2002 | 32 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2003 | 130 | 0.050 |
Why?
|
| Platinum | 1 | 2022 | 21 | 0.050 |
Why?
|
| Recurrence | 2 | 2018 | 600 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2002 | 62 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2015 | 509 | 0.050 |
Why?
|
| Alcohol Drinking | 3 | 2013 | 305 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 221 | 0.050 |
Why?
|
| Postoperative Period | 2 | 2017 | 126 | 0.050 |
Why?
|
| Cetuximab | 1 | 2021 | 8 | 0.050 |
Why?
|
| CpG Islands | 2 | 2013 | 212 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2013 | 125 | 0.050 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2021 | 25 | 0.050 |
Why?
|
| Career Choice | 1 | 2002 | 113 | 0.050 |
Why?
|
| Observer Variation | 2 | 2013 | 203 | 0.050 |
Why?
|
| DNA End-Joining Repair | 1 | 2021 | 24 | 0.050 |
Why?
|
| United States | 3 | 2017 | 7622 | 0.050 |
Why?
|
| Preoperative Care | 2 | 2017 | 177 | 0.050 |
Why?
|
| Time Factors | 3 | 2017 | 3618 | 0.050 |
Why?
|
| Bacteria | 1 | 2023 | 278 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 174 | 0.040 |
Why?
|
| Disease Progression | 2 | 2018 | 1054 | 0.040 |
Why?
|
| Carcinogens | 1 | 2020 | 37 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2013 | 82 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2019 | 21 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 148 | 0.040 |
Why?
|
| Oncogenes | 1 | 2020 | 69 | 0.040 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 2616 | 0.040 |
Why?
|
| Mouth Mucosa | 2 | 2012 | 23 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2012 | 35 | 0.040 |
Why?
|
| Mice, Inbred NOD | 2 | 2010 | 516 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 77 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 324 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 157 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 387 | 0.040 |
Why?
|
| Mutagens | 1 | 2018 | 19 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2018 | 10 | 0.040 |
Why?
|
| Fibroblasts | 2 | 2015 | 370 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2018 | 24 | 0.040 |
Why?
|
| Apoptosis | 3 | 2013 | 1040 | 0.040 |
Why?
|
| Fistula | 2 | 2009 | 13 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2003 | 2101 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 196 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 31 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2017 | 33 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2015 | 376 | 0.040 |
Why?
|
| Germ Cells | 1 | 2018 | 97 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2013 | 598 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2018 | 171 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 807 | 0.040 |
Why?
|
| Reoperation | 1 | 2017 | 269 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 261 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 1471 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2018 | 168 | 0.030 |
Why?
|
| DCC Receptor | 1 | 2015 | 2 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 774 | 0.030 |
Why?
|
| Cyclin A1 | 1 | 2015 | 3 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 583 | 0.030 |
Why?
|
| Neck | 1 | 2016 | 46 | 0.030 |
Why?
|
| Bias | 1 | 2016 | 106 | 0.030 |
Why?
|
| Nanostructures | 1 | 2018 | 174 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 255 | 0.030 |
Why?
|
| Autophagy | 1 | 2018 | 208 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 262 | 0.030 |
Why?
|
| Quercetin | 1 | 2015 | 24 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 405 | 0.030 |
Why?
|
| Sleep | 2 | 2009 | 223 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 132 | 0.030 |
Why?
|
| Smoking Prevention | 1 | 2016 | 162 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 139 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 197 | 0.030 |
Why?
|
| Income | 1 | 2016 | 162 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 176 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 2049 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2087 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 3218 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2015 | 267 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 90 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2013 | 37 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 372 | 0.030 |
Why?
|
| Exercise | 2 | 2013 | 918 | 0.030 |
Why?
|
| Pulse Therapy, Drug | 1 | 2013 | 2 | 0.030 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2013 | 8 | 0.030 |
Why?
|
| Child | 2 | 2014 | 4336 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2013 | 35 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 792 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 74 | 0.030 |
Why?
|
| Chorioallantoic Membrane | 1 | 2013 | 2 | 0.030 |
Why?
|
| rap1 GTP-Binding Proteins | 1 | 2013 | 3 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 56 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2013 | 50 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 242 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 406 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2004 | 292 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 116 | 0.030 |
Why?
|
| Speech Disorders | 1 | 2012 | 17 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 661 | 0.030 |
Why?
|
| Medical Audit | 1 | 2013 | 60 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2012 | 18 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 109 | 0.030 |
Why?
|
| Functional Food | 1 | 2012 | 36 | 0.030 |
Why?
|
| Decision Making | 1 | 2016 | 394 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2014 | 265 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 87 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 260 | 0.030 |
Why?
|
| Medical Records | 1 | 2013 | 139 | 0.030 |
Why?
|
| Vitamin B 12 | 1 | 2012 | 25 | 0.030 |
Why?
|
| Vitamin A | 1 | 2012 | 27 | 0.030 |
Why?
|
| DNA Primers | 1 | 2013 | 293 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 193 | 0.020 |
Why?
|
| Reference Values | 1 | 2013 | 322 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 190 | 0.020 |
Why?
|
| Bromhexine | 1 | 2012 | 1 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 252 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2012 | 78 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 472 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 531 | 0.020 |
Why?
|
| Sleep Wake Disorders | 1 | 2013 | 69 | 0.020 |
Why?
|
| Vitamins | 1 | 2012 | 82 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 187 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 157 | 0.020 |
Why?
|
| HIV Infections | 1 | 2017 | 927 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2010 | 82 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 160 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 1313 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 159 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 222 | 0.020 |
Why?
|
| Speech, Alaryngeal | 1 | 2009 | 3 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 643 | 0.020 |
Why?
|
| Speech Intelligibility | 1 | 2009 | 9 | 0.020 |
Why?
|
| Punctures | 1 | 2009 | 53 | 0.020 |
Why?
|
| Depression | 2 | 2008 | 868 | 0.020 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 943 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 558 | 0.020 |
Why?
|
| Marital Status | 1 | 2008 | 43 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2007 | 13 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2007 | 6 | 0.020 |
Why?
|
| Microdissection | 1 | 2007 | 5 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2007 | 24 | 0.020 |
Why?
|
| Hyoid Bone | 1 | 2007 | 3 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 1470 | 0.020 |
Why?
|
| Mucositis | 1 | 2007 | 7 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2007 | 84 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 1851 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 855 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2007 | 111 | 0.020 |
Why?
|
| Patient Admission | 1 | 2008 | 185 | 0.020 |
Why?
|
| Energy Intake | 1 | 2008 | 213 | 0.020 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2006 | 23 | 0.020 |
Why?
|
| Stomatitis | 1 | 2005 | 7 | 0.020 |
Why?
|
| Body Weight | 1 | 2007 | 381 | 0.020 |
Why?
|
| Motor Activity | 1 | 2008 | 343 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2008 | 454 | 0.010 |
Why?
|
| Tracheotomy | 1 | 2004 | 7 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2004 | 8 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 577 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2004 | 46 | 0.010 |
Why?
|
| Laryngeal Cartilages | 1 | 2003 | 3 | 0.010 |
Why?
|
| Skin | 1 | 2007 | 356 | 0.010 |
Why?
|
| Dioxanes | 1 | 2003 | 4 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 397 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 662 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2004 | 337 | 0.010 |
Why?
|
| Cell Count | 1 | 2003 | 129 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2003 | 106 | 0.010 |
Why?
|
| Laminin | 1 | 2003 | 76 | 0.010 |
Why?
|
| Exons | 1 | 2003 | 193 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 2003 | 63 | 0.010 |
Why?
|
| Polylysine | 1 | 2003 | 49 | 0.010 |
Why?
|
| Collagen | 1 | 2003 | 119 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2002 | 42 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2002 | 138 | 0.010 |
Why?
|
| Swine | 1 | 2003 | 349 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2002 | 105 | 0.010 |
Why?
|
| Gene Expression | 1 | 2003 | 807 | 0.010 |
Why?
|
| Length of Stay | 1 | 2004 | 781 | 0.010 |
Why?
|
| Polymers | 1 | 2003 | 317 | 0.010 |
Why?
|
| Insulin | 1 | 2003 | 689 | 0.010 |
Why?
|